Preclinical Safety Assessment Considerations in Vaccine Development
- 1 January 1995
- book chapter
- Published by Springer Nature
- Vol. 6, 61-79
- https://doi.org/10.1007/978-1-4615-1823-5_3
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Potential pitfalls on the road to an effective HIV vaccineImmunology Today, 1994
- Natural Autoantibodies Cross-React with a Peptide Derived from the Second Conserved Region of HIV-1 Envelope Glycoprotein gp120Biochemical and Biophysical Research Communications, 1993
- Coordinate Induction of Interferon α and γ by Recombinant HIV-1 Glycoprotein 120AIDS Research and Human Retroviruses, 1993
- Cytokine network and acute primary HIV-1 infectionAIDS, 1993
- Guillain-Barré syndrome following immunisation withHaemophilus influenzae type b conjugate vaccineEuropean Journal of Pediatrics, 1993
- Adjuvants: current status, clinical perspectives and future prospectsImmunology Today, 1993
- Current Thoughts on the Risks and Benefits of ImmunisationDrug Safety, 1993
- Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: A study with rat cerebellar granule cell culturesJournal of Neuroscience Research, 1993
- Risks and benefits of vaccinia-vectored vaccine use from the regulatory perspectiveResearch in Virology, 1989
- Guillain-Barré Syndrome and the 1978–1979 Influenza VaccineNew England Journal of Medicine, 1981